WallStSmart
FBLG

FibroBiologics, Inc. Common Stock

NASDAQ: FBLG · HEALTHCARE · BIOTECHNOLOGY

$0.87
+5.60% today

Updated 2026-08-05

Market cap
$3.83M
P/E ratio
P/S ratio
EPS (TTM)
$-6.97
Dividend yield
52W range
$1 – $14
Volume
0.1M

FibroBiologics, Inc. Common Stock (FBLG) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item202120222023202420252026
Revenue$0.00$0.00$0.00$0.00$0.00
Revenue growth (YoY)
Cost of revenue$94000.00$437000.00$573000.00$832000.00
Gross profit$-94000.00$-437000.00$-573000.00$-832000.00
Gross margin
R&D$669000.00$521000.00$1.15M$2.37M$4.50M$7.41M
SG&A$500000.00$1.06M$3.32M$6.52M$9.23M$9.24M
Operating income$-1.17M$-1.58M$-4.47M$-8.89M$-13.74M$-16.65M
Operating margin
EBITDA$-1.58M$-4.37M$-15.90M$-10.57M$-17.61M
EBITDA margin
EBIT$-4.47M$-16.34M$-11.14M$-18.44M
Interest expense$4000.00$654000.00$147000.00$20000.00$204000.00
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-1.17M$-1.58M$-5.12M$-16.48M$-11.16M$-18.65M
Net income growth (YoY)-35.3%-223.7%-221.9%+32.3%-67.1%
Profit margin

Frequently asked questions

How much free cash flow does FBLG generate?

FBLG produced $-16.66M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is FBLG's balance sheet healthy?

FBLG holds $4.89M in cash and equivalents against — in long-term debt, on $6.16M of shareholder equity. That debt is best read against the cash flow the business throws off each year.